Funding for this research was provided by:
(AI104621, AI114855, 1U19AI135995, AI115754)
Received: 2 October 2020
Accepted: 23 November 2020
First Online: 26 November 2020
Ethics approval and consent to participate
: The Tulane University Institutional Review Board (191330) and the Sierra Leone Ethics and Scientific Research Committee (070716) approved this project.
: Not applicable.
: JSS, LMB, RFG and DSG are members of the VHFC (ExternalRef removed). The VHFC is a partnership of academic and industry scientists who are developing diagnostic tests, therapeutic agents, and vaccines for Lassa fever, Ebola, and other severe diseases. Tulane University and its various academic and industry partners have filed US and foreign patent applications on behalf of the consortium for several of these technologies. Technical information may also be kept as trade secrets. If commercial products are developed, consortium members may receive royalties or profits. This does not alter our adherence to all policies of the NIH and <i>Virology Journal</i> on sharing data and materials. Financial and non-financial competing interests that the editors consider relevant to the content of the manuscript have been disclosed. RFG and LMB are co-founders of Zalgen. LMB is a Zalgen employee. All other authors declare no competing interests.